Fluorescent Imaging of Nerves With Illuminare-1 During Surgery

Inclusion Criteria: * 18 years or older and capable of signing their own consent form * Scheduled for minimally invasive radical prostatectomy with pelvic lymph node dissection Exclusion Criteria: * Prior pelvic surgery or pelvic radiation therapy * Known central nervous or peripheral nervous system disease or insult (including neurodegenerative diseases), current use of neurotoxic medications, or use of cytotoxic chemotherapy with known neurotoxicity within 1 month * Exposure to investigational agents in the immediate 30 days before or 15 days after study drug administration * Patients with significant renal dysfunction (\<60 mL/min as assessed by the Cockcroft Gault calculation for creatinine clearance) * Clinically significant hepatic/liver impairment (liver function tests more than 2x institutional normal upper limit) * Exposure to phototoxic drugs such as St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones, and tetracyclines, should be avoided. If safe to discontinue use for a limited time, patients may participate on this trial but will discontinue the use of the interfering drug for 5 half-lives before Illuminare-1 injection to permit full washout, as well as for 48 hours after administration of Illuminare-1.